This German Biotech's $6.5M Seed Could Change How We Treat Heart Disease

Jan de Vries · 2026-08-28

Let's talk about a new player that just entered the European biotech scene with a fresh idea. Revier Therapeutics, based in the historic city of Heidelberg, Germany, has officially launched. They're tackling some of the most stubborn heart conditions we face today, and they've just secured a solid $6.5 million Seed round to get their science moving. That's right, they've closed a significant initial funding round to chase their goal of developing new therapies for cardiometabolic diseases. It's a quiet launch for a company with a potentially loud impact. ### The Funding and The Backers The $6.5 million investment wasn't a solo act. The round was led by the KHAN Technology Transfer Fund II, a notable player in the tech transfer space. They brought along some serious co-investors, including High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors organized through Revier Invest Heidelberg. This kind of coalition—mixing institutional funds with regional private capital—often signals strong local belief in a startup's foundation. It’s not just about the money; it's about building a support network from the ground up. ### The Unmet Need in Cardiovascular Care So, what's the big problem Revier is trying to solve? The company's CEO, Prof. Eva van Rooij, puts it bluntly. "Despite significant progress in cardiovascular medicine," she says, "millions of patients... still face limited targeted treatment options." She's talking about conditions like HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease). For many living with these, managing symptoms is the current reality, not addressing the root cause. Revier's mission is to shift that focus. Their goal is to create the next generation of medicines that go after the underlying biology driving the disease. Think of it as fixing the engine, not just topping up the oil. ### A First-of-its-Kind Scientific Approach Here’s where it gets technically fascinating. Revier is pioneering the first therapeutic approach to selectively target a specific class of enzymes called class IIa histone deacetylases (HDACs) for cardiometabolic diseases. In simple terms, HDACs are like cellular regulators. When they malfunction, they can contribute to severe diseases. Older, first-generation HDAC inhibitors were a bit of a blunt instrument—they hit multiple HDAC classes, which often led to nasty side effects that limited how much medicine a patient could tolerate. Revier's science, led by founder Prof. Johannes Backs, is designed to be a precision tool. Their small-molecule drugs are taken orally and are engineered to be selective. They aim to inhibit only the specific, disease-causing activity of class IIa HDACs while leaving their healthy functions—and other critical enzymes—alone. - **Targeted Action:** Goes after the bad activity, spares the good. - **Oral Delivery:** Patients could take it as a pill, not an injection. - **Safety Focus:** Built from the ground up to avoid the side-effect pitfalls of older drugs. This precision could be the key to unlocking effective, long-term treatments where current options fall short. ### What Investors Are Saying The confidence from investors goes beyond the science. Michael Hamacher of KHAN Technology Transfer Fund II highlighted the team's potential. He pointed to Revier's "differentiated class IIa HDAC strategy" and its chance to "unlock the therapeutic promise of HDAC biology." For him, it's the combination of a novel approach with an "exceptional leadership team and deep scientific expertise" that creates the unique opportunity to reshape patient care. ### The Road Ahead With the $6.5 million in the bank, what's next? The capital has a clear job. It will fuel the preclinical development of their two lead programs: one for HFpEF and another for ASCVD. Beyond the lab work, the funding will also help them build out the operational, scientific, and clinical teams necessary to take a biotech from an idea to impacting patients. It's a classic startup journey, just in one of the most complex and regulated industries out there. They're not just building a company; they're attempting to build a new path for treating chronic, life-altering diseases. For professionals watching the European startup and biotech incorporation landscape, Revier Therapeutics is a name to remember—a German deep-tech venture aiming to make a very human difference.